# Teads Holding Co.: financial statements, quarterly

TEAD · Nasdaq · CIK 1454938 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tead.md) · [Financials](/companies/tead/financials.md) · [Filings](/companies/tead/filings.md) · [Insiders](/companies/tead/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tead/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [230](/filings/0001454938-24-000196.md) | [248 d](/filings/0001454938-26-000015.md) | [217](/filings/0001454938-25-000071.md) | [214](/filings/0001454938-25-000132.md) | [224](/filings/0001454938-25-000138.md) | [235 d](/filings/0001454938-26-000015.md) | [286](/filings/0001454938-26-000037.md) | [343](/filings/0001454938-26-000054.md) | [319](/filings/0001454938-25-000138.md) | [352 d](/filings/0001454938-26-000015.md) | [266](/filings/0001454938-26-000037.md) | [285](/filings/0001454938-26-000054.md) |
| Cost of revenue | $m | [184](/filings/0001454938-24-000196.md) | [195 d](/filings/0001454938-26-000015.md) | [175](/filings/0001454938-25-000071.md) | [169](/filings/0001454938-25-000132.md) | [175](/filings/0001454938-25-000138.md) | [179 d](/filings/0001454938-26-000015.md) | [204](/filings/0001454938-26-000037.md) | [223](/filings/0001454938-26-000054.md) | [213](/filings/0001454938-25-000138.md) | [232 d](/filings/0001454938-26-000015.md) | [182](/filings/0001454938-26-000037.md) | [189](/filings/0001454938-26-000054.md) |
| Gross profit | $m | [46.4](/filings/0001454938-24-000196.md) | [53.2 d](/filings/0001454938-26-000015.md) | [41.6](/filings/0001454938-25-000071.md) | [45.6](/filings/0001454938-25-000132.md) | [48.9](/filings/0001454938-25-000138.md) | [56.1 d](/filings/0001454938-26-000015.md) | [82.7](/filings/0001454938-26-000037.md) | [120](/filings/0001454938-26-000054.md) | [106](/filings/0001454938-25-000138.md) | [120 d](/filings/0001454938-26-000015.md) | [83.6](/filings/0001454938-26-000037.md) | [95.6](/filings/0001454938-26-000054.md) |
| Research and development | $m | [8.7](/filings/0001454938-24-000196.md) | [7.9 d](/filings/0001454938-26-000015.md) | [9.2](/filings/0001454938-25-000071.md) | [9.3](/filings/0001454938-25-000132.md) | [9.1](/filings/0001454938-25-000138.md) | [9.4 d](/filings/0001454938-26-000015.md) | [14.0](/filings/0001454938-26-000037.md) | [13.3](/filings/0001454938-26-000054.md) | [10.7](/filings/0001454938-25-000138.md) | [5.5 d](/filings/0001454938-26-000015.md) | [10.7](/filings/0001454938-26-000037.md) | [11.4](/filings/0001454938-26-000054.md) |
| Operating income | $m | [2.6](/filings/0001454938-24-000196.md) | [5.7 d](/filings/0001454938-26-000015.md) | [(6.6)](/filings/0001454938-25-000071.md) | [(5.6)](/filings/0001454938-25-000132.md) | [(2.9)](/filings/0001454938-25-000138.md) | [2.5 d](/filings/0001454938-26-000015.md) | [(44.4)](/filings/0001454938-26-000037.md) | [(2.3)](/filings/0001454938-26-000054.md) | [(6.3)](/filings/0001454938-25-000138.md) | [(346) d](/filings/0001454938-26-000015.md) | [(21.8)](/filings/0001454938-26-000037.md) | [(15.6)](/filings/0001454938-26-000054.md) |
| Interest expense | $m | [1.5](/filings/0001454938-23-000151.md) | [1.0 d](/filings/0001454938-24-000024.md) | [0.9](/filings/0001454938-24-000074.md) | [0.6](/filings/0001454938-24-000157.md) | [1.4](/filings/0001454938-25-000138.md) | [0.7 d](/filings/0001454938-26-000015.md) | [23.1](/filings/0001454938-26-000037.md) | [17.5](/filings/0001454938-26-000054.md) | [17.1](/filings/0001454938-25-000138.md) | [17.4 d](/filings/0001454938-26-000015.md) | [17.4](/filings/0001454938-26-000037.md) | [17.4](/filings/0001454938-26-000054.md) |
| Income tax | $m | [1.0](/filings/0001454938-24-000196.md) | [2.7 d](/filings/0001454938-26-000015.md) | [(1.1)](/filings/0001454938-25-000071.md) | [(1.3)](/filings/0001454938-25-000132.md) | [1.2](/filings/0001454938-25-000138.md) | [3.5 d](/filings/0001454938-26-000015.md) | [(13.2)](/filings/0001454938-26-000037.md) | [(5.8)](/filings/0001454938-26-000054.md) | [(4.7)](/filings/0001454938-25-000138.md) | [63.0 d](/filings/0001454938-26-000015.md) | [(1.0)](/filings/0001454938-26-000037.md) | [7.3](/filings/0001454938-26-000054.md) |
| Net income | $m | [0.5](/filings/0001454938-24-000196.md) | [4.1 d](/filings/0001454938-26-000015.md) | [(5.0)](/filings/0001454938-25-000138.md) | [(2.2)](/filings/0001454938-25-000138.md) | [6.7](/filings/0001454938-25-000138.md) | [(0.2) d](/filings/0001454938-26-000015.md) | [(54.8)](/filings/0001454938-26-000054.md) | [(14.3)](/filings/0001454938-26-000054.md) | [(19.7)](/filings/0001454938-25-000138.md) | [(428) d](/filings/0001454938-26-000015.md) | [(38.8)](/filings/0001454938-26-000054.md) | [(42.5)](/filings/0001454938-26-000054.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001454938-24-000196.md) | not reported | [(0.10)](/filings/0001454938-25-000071.md) | [(0.04)](/filings/0001454938-25-000132.md) | [0.01](/filings/0001454938-25-000138.md) | not reported | [(0.70)](/filings/0001454938-26-000037.md) | [(0.15)](/filings/0001454938-26-000054.md) | [(0.21)](/filings/0001454938-25-000138.md) | not reported | [(0.40)](/filings/0001454938-26-000037.md) | [(0.44)](/filings/0001454938-26-000054.md) |
| Basic EPS | $ per share | [0.01](/filings/0001454938-24-000196.md) | not reported | [(0.10)](/filings/0001454938-25-000071.md) | [(0.04)](/filings/0001454938-25-000132.md) | [0.14](/filings/0001454938-25-000138.md) | not reported | [(0.70)](/filings/0001454938-26-000037.md) | [(0.15)](/filings/0001454938-26-000054.md) | [(0.21)](/filings/0001454938-25-000138.md) | not reported | [(0.40)](/filings/0001454938-26-000037.md) | [(0.44)](/filings/0001454938-26-000054.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.5](/filings/0001454938-24-000196.md) | [70.9](/filings/0001454938-26-000015.md) | [71.4](/filings/0001454938-25-000071.md) | [75.1](/filings/0001454938-25-000132.md) | [57.1](/filings/0001454938-25-000138.md) | [89.1](/filings/0001454938-26-000015.md) | [136](/filings/0001454938-26-000037.md) | [149](/filings/0001454938-26-000054.md) | [131](/filings/0001454938-25-000138.md) | [128](/filings/0001454938-26-000054.md) | [85.5](/filings/0001454938-26-000037.md) | [88.0](/filings/0001454938-26-000054.md) |
| Current assets | $m | [387](/filings/0001454938-23-000151.md) | [402](/filings/0001454938-25-000020.md) | [359](/filings/0001454938-24-000074.md) | [357](/filings/0001454938-24-000157.md) | [326](/filings/0001454938-24-000196.md) | [343](/filings/0001454938-26-000015.md) | [534](/filings/0001454938-25-000071.md) | [551](/filings/0001454938-25-000132.md) | [494](/filings/0001454938-25-000138.md) | [530](/filings/0001454938-26-000054.md) | [426](/filings/0001454938-26-000037.md) | [406](/filings/0001454938-26-000054.md) |
| Total assets | $m | [630](/filings/0001454938-23-000151.md) | [665](/filings/0001454938-25-000020.md) | [627](/filings/0001454938-24-000074.md) | [626](/filings/0001454938-24-000157.md) | [530](/filings/0001454938-24-000196.md) | [549](/filings/0001454938-26-000015.md) | [1,688](/filings/0001454938-25-000071.md) | [1,775](/filings/0001454938-25-000132.md) | [1,712](/filings/0001454938-25-000138.md) | [1,328](/filings/0001454938-26-000054.md) | [1,202](/filings/0001454938-26-000037.md) | [1,162](/filings/0001454938-26-000054.md) |
| Current liabilities | $m | [267](/filings/0001454938-23-000151.md) | [298](/filings/0001454938-25-000020.md) | [261](/filings/0001454938-24-000074.md) | [261](/filings/0001454938-24-000157.md) | [273](/filings/0001454938-24-000196.md) | [289](/filings/0001454938-26-000015.md) | [473](/filings/0001454938-25-000071.md) | [503](/filings/0001454938-25-000132.md) | [455](/filings/0001454938-25-000138.md) | [484](/filings/0001454938-26-000054.md) | [409](/filings/0001454938-26-000037.md) | [413](/filings/0001454938-26-000054.md) |
| Total liabilities | $m | [412](/filings/0001454938-23-000151.md) | [442](/filings/0001454938-25-000020.md) | [410](/filings/0001454938-24-000074.md) | [410](/filings/0001454938-24-000157.md) | [303](/filings/0001454938-24-000196.md) | [318](/filings/0001454938-26-000015.md) | [1,213](/filings/0001454938-25-000071.md) | [1,243](/filings/0001454938-25-000132.md) | [1,193](/filings/0001454938-25-000138.md) | [1,233](/filings/0001454938-26-000054.md) | [1,152](/filings/0001454938-26-000037.md) | [1,155](/filings/0001454938-26-000054.md) |
| Long-term debt | $m | [118](/filings/0001454938-23-000151.md) | [118](/filings/0001454938-25-000020.md) | [118](/filings/0001454938-24-000074.md) | [118](/filings/0001454938-24-000157.md) | [0.0](/filings/0001454938-24-000196.md) | [0.0](/filings/0001454938-26-000015.md) | [611](/filings/0001454938-25-000071.md) | [603](/filings/0001454938-25-000132.md) | [604](/filings/0001454938-25-000138.md) | [605](/filings/0001454938-26-000054.md) | [606](/filings/0001454938-26-000037.md) | [607](/filings/0001454938-26-000054.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001454938-26-000015.md) | [16.2](/filings/0001454938-25-000071.md) | [17.6](/filings/0001454938-25-000132.md) | [17.6](/filings/0001454938-25-000138.md) | [17.6](/filings/0001454938-26-000054.md) | [17.2](/filings/0001454938-26-000037.md) | [7.1](/filings/0001454938-26-000054.md) |
| Shareholders' equity | $m | [218](/filings/0001454938-24-000196.md) | [223](/filings/0001454938-26-000015.md) | [217](/filings/0001454938-25-000138.md) | [216](/filings/0001454938-25-000138.md) | [227](/filings/0001454938-25-000138.md) | [231](/filings/0001454938-26-000054.md) | [475](/filings/0001454938-26-000054.md) | [532](/filings/0001454938-26-000054.md) | [519](/filings/0001454938-25-000138.md) | [95.4](/filings/0001454938-26-000054.md) | [50.3](/filings/0001454938-26-000054.md) | [7.4](/filings/0001454938-26-000054.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [6.9 d](/filings/0001454938-24-000196.md) | [25.5 d](/filings/0001454938-26-000015.md) | [8.6](/filings/0001454938-25-000071.md) | [3.6 d](/filings/0001454938-25-000132.md) | [13.7 d](/filings/0001454938-25-000138.md) | [42.7 d](/filings/0001454938-26-000015.md) | [(1.0)](/filings/0001454938-26-000037.md) | [25.0 d](/filings/0001454938-26-000054.md) | [(23.7) d](/filings/0001454938-25-000138.md) | [7.3 d](/filings/0001454938-26-000015.md) | [(34.9)](/filings/0001454938-26-000037.md) | [9.2 d](/filings/0001454938-26-000054.md) |
| Capital expenditure | $m | [2.8 d](/filings/0001454938-24-000196.md) | [2.3 d](/filings/0001454938-26-000015.md) | [1.3](/filings/0001454938-25-000071.md) | [0.8 d](/filings/0001454938-25-000132.md) | [2.5 d](/filings/0001454938-25-000138.md) | [2.7 d](/filings/0001454938-26-000015.md) | [2.9](/filings/0001454938-26-000037.md) | [1.1 d](/filings/0001454938-26-000054.md) | [0.8 d](/filings/0001454938-25-000138.md) | [0.8 d](/filings/0001454938-26-000015.md) | [0.7](/filings/0001454938-26-000037.md) | [1.1 d](/filings/0001454938-26-000054.md) |
| Share repurchases | $m | [5.7 d](/filings/0001454938-24-000196.md) | [5.3 d](/filings/0001454938-26-000015.md) | [4.0](/filings/0001454938-25-000071.md) | [2.2 d](/filings/0001454938-25-000132.md) | [0.2 d](/filings/0001454938-25-000138.md) | [0.2 d](/filings/0001454938-26-000015.md) | [0.4](/filings/0001454938-26-000037.md) | [0.2 d](/filings/0001454938-26-000054.md) | [0.1 d](/filings/0001454938-25-000138.md) | [0.0 d](/filings/0001454938-26-000015.md) | [0.0](/filings/0001454938-26-000037.md) | [0.1 d](/filings/0001454938-26-000054.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q2 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.2](/filings/0001454938-23-000151.md) | [51.4](/filings/0001454938-24-000074.md) | [56.6](/filings/0001454938-24-000157.md) | [51.2](/filings/0001454938-24-000196.md) | [49.3](/filings/0001454938-25-000071.md) | [48.9](/filings/0001454938-25-000132.md) | [53.9](/filings/0001454938-25-000138.md) | [78.0](/filings/0001454938-26-000037.md) | [94.5](/filings/0001454938-26-000054.md) | [95.1](/filings/0001454938-25-000138.md) | [96.3](/filings/0001454938-26-000037.md) | [97.3](/filings/0001454938-26-000054.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 98,065,162 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001454938-26-000054.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.